Effect of doxofylline combined with cefoperazone sulbactam sodium in the treatment of severe pneumonia
Objective:To study the effect of doxofylline combined with cefoperazone sulbactam sodium in the treatment of patients with severe pneumonia.Methods:A total of 115 patients with severe pneumonia admitted to our hospital from September 2021 to January 2023 were enrolled in the study.They were divided into control group(57 cases)and combined group(58 cases)by random number table method.The control group was treated with cefoperazone sulbactam sodium,and the combined group was treated with doxofylline on this basis.The clinical efficacy,lung function indexes[peak expiratory flow(PEF),forced vital capacity(FVC),forced expiratory volume in the first second(FEV1),FEV1/FVC],blood gas indexes[arterial partial pressure of oxygen(PaO2),partial pressure of carbon dioxide(PaCO2),oxygen saturation(SaO2)],peripheral blood Treg/Th17 levels(Treg cell count,Th17 cell count,Treg/Th17),peripheral blood interleukin-17(IL-17)and IL-10 levels were compared between the two groups before and after treatment.Results:The total effective rate of treatment in the combined group was 98.28%,which was higher than 85.96%in the control group,and the difference was statistically significant(P＜0.05).PEF,FVC,FEV1 and FEV1/FVC in the combined group were higher than those in the control group,and the differences were statistically significant(P＜0.05).PaO2 and SaO2 in the combined group were higher than those in the control group,and PaCO2 was lower than that in the control group(P＜0.05).The levels of peripheral blood Treg cells,Treg/Th17 and IL-10 in the combined group were lower than those in the control group,and the differences were statistically significant(P＜0.05).Conclusion:The combination of doxofylline in the treatment of severe pneumonia has a significant effect,which can effectively improve the blood gas index and lung function of patients,and also help to reduce the inflammatory response and regulate the body's immunity.
NETL
NSTL
万方数据
